Registry of Lobbyists
Subject matters | Details | Categories |
---|---|---|
Economic Development,
Health
|
Canada’s Innovation and Skills Plan, led by Innovation, Science and Economic Development Canada, with respect to ensuring that the life sciences sector is a major focus of the government’s post-COVID recovery plan
|
Policies or Program
|
Economic Development,
Health
|
Engagement with federal officials regarding Innovation, Science and Economic Development Canada’s plans for the creation of new biomanufacturing capacity for Canada
|
Policies or Program
|
Health
|
Engagement with officials regarding Health Canada’s proposed development of a strategy for drugs for rare disorders and other aspects of national pharmacare, including proposals for a Canada Drug Agency and a national formulary
|
Policies or Program
|
Health
|
Guidelines, policies and programs related to regulatory and reporting functions of the Patented Medicine Prices Review Board
|
Policies or Program,
Regulation
|
Health
|
Health Canada Regulations Amending the Patented Medicines Regulations (Additional Factors and Information Reporting Requirements) (SOR/2019-298) published in the Canada Gazette Part 2 on August 21, 2019
|
Regulation
|
Subject matters | Details | Categories |
---|---|---|
Subject matters were not required to be associated with subject matter details when this content was submitted
|
Canada’s Innovation and Skills Plan, led by Innovation, Science and Economic Development Canada, with respect to ensuring that the life sciences sector is a major focus of the government’s post-COVID recovery plan
|
Policies or Program
|
Subject matters were not required to be associated with subject matter details when this content was submitted
|
Engagement with federal officials regarding Innovation, Science and Economic Development Canada’s plans for the creation of new biomanufacturing capacity for Canada
|
Policies or Program
|
Subject matters were not required to be associated with subject matter details when this content was submitted
|
Engagement with officials regarding Health Canada’s proposed development of a strategy for drugs for rare disorders and other aspects of national pharmacare, including proposals for a Canada Drug Agency and a national formulary
|
Policies or Program
|
Subject matters were not required to be associated with subject matter details when this content was submitted
|
Guidelines, policies and programs related to regulatory and reporting functions of the Patented Medicine Prices Review Board
|
Policies or Program,
Regulation
|
Subject matters were not required to be associated with subject matter details when this content was submitted
|
Health Canada Regulations Amending the Patented Medicines Regulations (Additional Factors and Information Reporting Requirements) (SOR/2019-298) published in the Canada Gazette Part 2 on August 21, 2019
|
Regulation
|
Communication techniques that have been used or are expected to be used in the course of the undertaking: